Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Clinical nutrition products are aimed at maintaining a nutritional balance in patients, by providing sufficient amount of nutrients such as vitamins, proteins, and minerals. The clinical nutrition products are specially formulated to nourish and improve the quality of life for people of all ages, which is, in turn, favoring the growth of clinical nutrition market. Oral administration of clinical nutrition products is not viable in patients with severe infection or burns and those recovering from major surgery or acute trauma. Nutritional need in such patients can be met by specialized nutritional feeding known as enteral or parenteral feeding. The enteral nutrition is a segment of clinical nutrition, which includes liquid formula diets and it is administered by feeding tubes into the gastro intestinal tract. Whereas, parenteral feeding is the clinical nutrition administered by the intravascular route.
The Canada clinical nutrition market is estimated to be valued at US$ 593.0 million in 2021 and is expected to exhibit a CAGR of 4.9% over the forecast period (2021-2028).
Figure 1. Canada Clinical Nutrition Market Value (US$ Mn), by Nutrition Type, 2021
Rising prevalence of chronic diseases is expected to favor the growth of Canada clinical nutrition market
The increasing prevalence of chronic diseases such as diabetes and chronic kidney disease is resulting in increased risk of malnutrition, which is expected to drive the Canada clinical nutrition market growth. Clinical nutrition plays a crucial role in reducing complications associated with certain chronic conditions such as type 2 diabetes and chronic kidney disease (CKD).
According to the article published in the Canadian Journal of Diabetes in 2018, the estimated prevalence of diabetes in Canada was 3.4 million or 9.3% of the population, and is predicted to rise to five million or 12.1% of the population by 2025, representing 44% increase from 2015 to 2025.
According to the report published by Kidney Foundation in March 2020, 1 in 10 people suffer from kidney disease in Canada which totals to 4 million people and more than 50,000 Canadians were treated for kidney failure.
Canada Clinical Nutrition Market Report Coverage
||Market Size in 2021:
||US$ 593.0 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2022 to 2028 CAGR:
||2028 Value Projection:
||US$ 828.5 Mn
- By Nutrition Type:
- Enteral Nutrition: Standard Nutrition, Disease Specific Nutrition
- Parenteral Nutrition: Amino Acid, Carbohydrates, Vitamins and Minerals, Others
- By Form: Powder, Liquid, Others
- By Age Group: Infant Nutrition, Adult Nutrition, Geriatric Nutrition
- By Application: Diabetes, Cancer, Critical Care, Neurological Disorder, Metabolic Syndrome, Gastrointestinal Diseases, Other Applications
- By End User: Hospitals, Ambulatory Surgical Centers, Long Term Care Facilities
Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, NESTLÉ S.A., DANONE S.A., B.Braun Melsungen AG, Mead Johnson & Company, LLC, Perrigo Company PLC, Koru Nutrition Inc., and Koninklijke DSM N.V.
- Rising prevalence of chronic diseases
- Increasing number of product launches
|Restraints & Challenges:
- Side effects due to excessive consumption of clinical nutrition products
Figure 2. Canada Clinical Nutrition Market Share (%), by Age Group, (2021-2028)
Increasing number of product launches is expected to drive the segment growth over the forecast period.
Various manufacturers are engaged in development and launches of innovative and novel clinical nutrition products, which are expected to drive the growth of the Canada clinical nutrition market.
In November 2020, Abbott Laboratories, launched its most innovative infant formula, Similac Pro-Advance with 2'-Fucosyllactose Oligosaccharide† (2'-FL†), which is the first product in Canada with this breakthrough ingredient in infant formula.
In September 2018, Baxter Canada, a subsidiary of Baxter International received Health Canada approval for OLIMEL 7.6% and OLIMEL 7.6% E (amino acids, dextrose, lipids with/without electrolytes, injectable emulsion), which is indicated for parenteral nutrition for adults, when oral or enteral nutrition is impossible, insufficient, or contraindicated.
Canada Clinical Nutrition Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdown in Canada have impacted the financial situation of several business sectors. Private healthcare is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of nutritional products and affected growth of the nutrition and healthcare businesses of various clinical nutrition companies. The COVID-19 pandemic has restricted access to healthcare facilities and community services. Consequently, this is increasing the risk of individuals developing malnutrition. Hence, in such critical times, nutrition plays an essential role in building immunity. Though the demand for clinical nutrients is high, the restriction imposed has hampered the supply to a certain extent.
Thus, COVID-19 pandemic has affected the economy in three main ways: 1) By directly affecting the production and demand; 2) By creating disruptions in distribution channels; and 3) By its financial impact on firms and financial markets.
The decreased access to nutrition care services and healthcare professionals owing to limited in-person contact and service cancellations was among the most common challenge that Canadian dietitians reported for discharged patients. However, the pandemic brought a drastic shift in healthcare practices such as the healthcare professionals started taking appointments over call or other virtual services thus, improving the market scenario.
Canada Clinical Nutrition Market - Restraint
The major factors restraining growth of the Canada clinical nutrition market include side effects and complications caused by excessive consumption of products indicated for clinical nutrition. Excess consumption of any nutritional product can lead to life threating conditions. For instance, parenteral nutritional therapy can lead to serious and life threating conditions such as liver dysfunction.
According to a study published in the Annals of Internal Medicine journal, in December 2013, vitamin use was more among elderly Americans, almost 50% of individuals consumed vitamins between the 50 to 64 age group. According to the report, excessive vitamins do not provide health benefits and may even cause harm such as increased urination and uneven heart rate. Furthermore, most supplements do not prevent chronic disease or death.
Major players operating in the Canada clinical nutrition market include Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, NESTLÉ S.A., DANONE S.A., B. Braun Melsungen AG, Mead Johnson & Company, LLC, Perrigo Company PLC, Koru Nutrition Inc., and Koninklijke DSM N.V.